

In the specification, please replace the paragraph located on page 6 at lines 28-34 with the following replacement paragraph:

The amino acid sequence (Y) linked carboxy-terminally to the 2,3-diacyloxypropyl-substituted amino acid is preferably selected from the following sequences:

- a) GQTNT (SEQ ID NO: 1),
- b) SKKKK (SEQ ID NO: 2),
- c) GNNDESNISFKEK (SEQ ID NO: 3) or
- d) GQTDNNSSQSAAPGSGTTNT (SEQ ID NO: 4).

In the specification, please replace the paragraph located on page 8 at lines 11-22 with the following replacement paragraph:

The lipopeptide or lipoprotein of the invention is obtained in particular by synthesis.

Lipopeptides of the invention might also be obtained by methods generally known in the art from a mycoplasma clone and particularly advantageously from a *Mycoplasma fermentans* clone. The lipopeptides of the invention are also referred to as MALP, namely as "macrophage-activating lipopeptides". These include different variants, of which MALP-2 is a 2kDa lipopeptide according to formula (I) with Y = GNNDESNISFKEK (SEQ ID NO: 3); R₃, R₄ = H and R₁, R₂ = palmitoyl(C15) (S-(2,3-bispalmitoyloxypropyl)cysteinyl-GNNDESNISFKEK (SEQ ID NO: 3)).

In the specification, please replace the paragraph located on page 14 at lines 19-30 with the following replacement paragraph:

The investigations described in the examples were mainly carried out with a synthetic MALP-2, which substantially corresponds to a lipopeptide derived from mycoplasma, as mucosal adjuvant together with β -galactosidase as model antigen. This specific exemplary lipopeptide was selected on the basis of its previously determined intrinsic properties (biochemical properties, macrophage-stimulating activity). Unless indicated otherwise, the synthetic lipopeptide S-[2,3-bispalmitoyloxypropyl]cysteinyl-GNNDESNISFKEK (SEQ ID NO: 3) which was used in the examples is always referred to simply as "MALP-2" hereinafter.